Latest ACR News
-
Imagine a world where the multiple drugs in Phase 2 and 3 trials actually get approved, and we get access to them? I know you may be thinking that I am overly optimistic, but there are so many drugs in development in lupus that we may have true difficulty choosing what to use.Read Article

Dr Irwin Lim _connectedcare
Hand OA responds to 10mg/d Pred over 6wks. As expected symptoms return on cessation Anecdotally, there are people who do well on pragmatic, long term low dose eg 5mg or less/d #ACR19 @rheumnow Abst1760 https://t.co/FtE9vHb655


Dr. John Cush RheumNow

Dr. John Cush RheumNow

Jonathan Hausmann MD hausmannMD
CAPS is caused by mutations in NLRP3, a component of the inflammasome. It is thought that NLRP3 mutations lead to the uncontrolled production of the inflammatory cytokine IL-1b.

Jonathan Hausmann MD hausmannMD

Jonathan Hausmann MD hausmannMD

Jonathan Hausmann MD hausmannMD

Jonathan Hausmann MD hausmannMD

Jonathan Hausmann MD hausmannMD

Jonathan Hausmann MD hausmannMD

Dr. Antoni Chan synovialjoints
The highlight of the last day of #ACR19 is the Rheumatology Roundup Highlights #ACRBest by Drs. John Cush @RheumNow and Arthur Kavanaugh @ACRheum always worth attending with great take home messages #rheum https://t.co/eMdvc2byKG
